(NASDAQ: INCY) Incyte's forecast annual revenue growth rate of 8.67% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.82%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.32%.
Incyte's revenue in 2025 is $4,413,226,000.On average, 10 Wall Street analysts forecast INCY's revenue for 2025 to be $909,707,456,064, with the lowest INCY revenue forecast at $888,098,857,192, and the highest INCY revenue forecast at $932,943,203,802. On average, 10 Wall Street analysts forecast INCY's revenue for 2026 to be $1,006,590,175,881, with the lowest INCY revenue forecast at $959,964,405,169, and the highest INCY revenue forecast at $1,066,407,737,595.
In 2027, INCY is forecast to generate $1,094,677,271,467 in revenue, with the lowest revenue forecast at $1,030,907,011,700 and the highest revenue forecast at $1,226,720,421,235.